Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)

Phase 2 Completed 61 enrolled French National Agency for Research on AIDS and Viral Hepatitis Bristol-Myers Squibb · collab GlaxoSmithKline · collab Hoffmann-La Roche · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate virological efficacy and safety of two double protease inhibitor regimens: atazanavir/fosamprenavir/ritonavir 300 mg once daily/ 700/100 mg twice daily, versus atazanavir/saquinavir/ritonavir 300/1500/100 mg once daily in protease inhibitor naive HIV-1 patients.

Timeline

Start: 2005-12
Primary completion: —
Completion: 2007-08

Publications

Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vezinet F, Aboulker JP, Yeni P; ANRS 127 Study Group. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. J Antimicrob Chemother. 2009 Jul;64(1):118-25. doi: 10.1093/jac/dkp146. Epub 2009 May 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fosamprenavir	Small molecule	700 mg	—
Subject	Saquinavir	Small molecule	500 mg	—
Background	Atazanavir	Other / unclassified	150 mg	—
Background	Ritonavir	Other / unclassified	100 mg	—

Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)

Summary

Timeline

Publications

Drugs

Indications